News

An agreement between Catalyst Pharmaceuticals and Teva Pharmaceuticals has ended a U.S. patent litigation case that began when Teva applied to produce and market a generic version of Firdapse (amifampridine) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Under the terms of the settlement, announced…

Anti-CD19 CAR T-cell therapy was found to be effective in treating a 54-year-old man with Lambert-Eaton myasthenic syndrome (LEMS) who wasn’t responding to other immune-suppressing and symptomatic treatments, according to a case report from researchers in Germany. The team’s observations suggest that this type of cell therapy may be…

The National Organization for Rare Disorders (NORD) is offering a financial support program to aid people with Lambert-Eaton myasthenic syndrome (LEMS) and their caregivers. The LEMS Patient Assistance Program can provide financial support to cover out-of-pocket healthcare costs linked directly to treatment and care for the autoimmune disease, according…

Firdapse (amifampridine) has been approved in Japan to treat people with Lambert-Eaton myasthenic syndrome (LEMS). The therapy will be supplied in the form of oral tablets containing 10 mg of amifampridine, according to Catalyst Pharmaceuticals, the company that holds Firdapse’s licensing rights in North America. In collaboration with…

Firdapse (amifampridine) can help ease symptoms of Lambert-Eaton myasthenic syndrome (LEMS) in patients who don’t have an underlying cancer and its efficacy is consistent regardless of how long a delay there is before it’s started. That’s according to a study, “Safety, efficacy and steroid-sparing…

Lambert‐Eaton myasthenic syndrome (LEMS) may, in rare cases, manifest with severe respiratory muscle weakness leading to respiratory failure, researchers noted in a case study. “Establishing the association of LEMS with respiratory disease could lead to timely identification of LEMS, diagnosis of an underlying malignancy (if unknown), and initiation of…

People with Lambert-Eaton myasthenic syndrome (LEMS) have a lower quality of life and a higher disease burden than do those with myasthenia gravis (MG) or adults in the general population, according to a survey-based study in Germany. “Quality of life reflects one aspect of the burden of disease.

The U.S. Food and Drug Administration (FDA) has approved increasing from 80 to 100 mg the maximum recommended daily dose of Firdapse (amifampridine) for adults and children weighing at least 45 kg (about 99 pounds) with Lambert-Eaton myasthenic syndrome (LEMS). The decision follows a supplemental new drug application…

A man in his 60s who developed Lambert-Eaton myasthenic syndrome (LEMS) secondary to prostate cancer saw his neurological symptoms ease after receiving treatment with amifampridine — the active ingredient in the approved LEMS therapy Firdapse. That’s according to a report detailing the man’s case, unusual, per the researchers,…

The inaugural Lambert-Eaton myasthenic syndrome (LEMS) Awareness Day — which will be held each year on March 30 to call attention to the rare autoimmune disorder — was “fantastic,” according to the nonprofit association that created the event. “We appreciate everything everyone did for this first LEMS Awareness Day,…